CN114340669A - 用于增强抗体药物的效果的组合物 - Google Patents

用于增强抗体药物的效果的组合物 Download PDF

Info

Publication number
CN114340669A
CN114340669A CN202080061449.2A CN202080061449A CN114340669A CN 114340669 A CN114340669 A CN 114340669A CN 202080061449 A CN202080061449 A CN 202080061449A CN 114340669 A CN114340669 A CN 114340669A
Authority
CN
China
Prior art keywords
antibody
glucan
group
mouse
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080061449.2A
Other languages
English (en)
Chinese (zh)
Inventor
梨井康
藤野真之
守屋祐生子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aureo Co ltd
National Center for Child Health and Development
Original Assignee
Aureo Co ltd
National Center for Child Health and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aureo Co ltd, National Center for Child Health and Development filed Critical Aureo Co ltd
Priority to CN202510792626.9A priority Critical patent/CN120678911A/zh
Publication of CN114340669A publication Critical patent/CN114340669A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202080061449.2A 2019-09-11 2020-09-10 用于增强抗体药物的效果的组合物 Pending CN114340669A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510792626.9A CN120678911A (zh) 2019-09-11 2020-09-10 用于增强抗体药物的效果的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-165722 2019-09-11
JP2019165722 2019-09-11
PCT/JP2020/034361 WO2021049587A1 (ja) 2019-09-11 2020-09-10 抗体医薬の効果増強用組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510792626.9A Division CN120678911A (zh) 2019-09-11 2020-09-10 用于增强抗体药物的效果的组合物

Publications (1)

Publication Number Publication Date
CN114340669A true CN114340669A (zh) 2022-04-12

Family

ID=74865712

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080061449.2A Pending CN114340669A (zh) 2019-09-11 2020-09-10 用于增强抗体药物的效果的组合物
CN202510792626.9A Pending CN120678911A (zh) 2019-09-11 2020-09-10 用于增强抗体药物的效果的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510792626.9A Pending CN120678911A (zh) 2019-09-11 2020-09-10 用于增强抗体药物的效果的组合物

Country Status (5)

Country Link
US (1) US12377116B2 (https=)
EP (1) EP4029509A4 (https=)
JP (1) JP7088502B2 (https=)
CN (2) CN114340669A (https=)
WO (1) WO2021049587A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240285672A1 (en) * 2021-06-22 2024-08-29 Gn Corporation Co Ltd Beta-glucan for preventing and/or treating fibrosis and related diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002204687A (ja) * 2000-11-09 2002-07-23 Onaka Yasushi β−１．３−１．６グルカン（アウレオバシジウム培養液）の医療、保健、福祉、食品および各種産業分野での応用
KR20070034211A (ko) * 2005-09-23 2007-03-28 주식회사 글루칸 β-글루칸을 포함하는 항암 및 면역 기능 증강용 약학조성물
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
WO2016073763A2 (en) * 2014-11-06 2016-05-12 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
WO2017120604A1 (en) * 2016-01-08 2017-07-13 Biothera, Inc. Beta-glucan immunotherapies affecting the immune microenvironment
CN107106687A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5331482B2 (https=) 1974-05-18 1978-09-02
JPS5115632A (ja) 1974-06-22 1976-02-07 Kumiai Chemical Industry Co Satsuchusatsudanizai
JPS5480312A (en) 1977-12-08 1979-06-27 Asahi Glass Co Ltd Roll for use in production of float glass
JPS5937029B2 (ja) 1979-02-26 1984-09-07 三菱化学株式会社 陰極電着塗装法
US8883760B2 (en) * 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
JP4000078B2 (ja) 2003-03-07 2007-10-31 株式会社アウレオ 皮膚用保湿剤
JP4054697B2 (ja) 2003-03-07 2008-02-27 株式会社アウレオ 便秘改善剤
JP4369258B2 (ja) 2004-02-05 2009-11-18 株式会社アウレオ 免疫賦活剤
JP4268105B2 (ja) * 2004-09-09 2009-05-27 株式会社アウレオ β−グルカン含有組成物、その製造方法及び該組成物を含む飲食品若しくは皮膚用保湿剤
US20100068184A1 (en) 2006-11-02 2010-03-18 Aureo Co., Ltd. Living body healing accelerator
TWI496578B (zh) 2009-10-08 2015-08-21 Aureo Co Ltd 流感病毒感染症的治療劑
EP2508190B1 (en) 2009-12-03 2021-06-02 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
JP5242855B2 (ja) 2010-07-29 2013-07-24 国立大学法人北海道大学 免疫アジュバント
JP5554221B2 (ja) 2010-12-13 2014-07-23 株式会社アウレオ ウシの乳房炎の予防・治療用組成物及びウシの乳房炎の予防・治療方法
JP5937029B2 (ja) 2013-02-21 2016-06-22 国立大学法人北海道大学 Ｔｒａｉｌ発現亢進剤
JP6380968B2 (ja) 2013-10-22 2018-08-29 株式会社アウレオ 脂肪蓄積抑制剤
JP6293187B2 (ja) 2016-03-22 2018-03-14 株式会社アウレオ 造血機能増進用の組成物、及び貧血の予防及び／又は改善用の組成物
JP2023531611A (ja) * 2020-06-16 2023-07-25 株式会社ソフィ 免疫増強および／または免疫均衡維持のためのならびにアジュバント使用のためのベータグルカン

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002204687A (ja) * 2000-11-09 2002-07-23 Onaka Yasushi β−１．３−１．６グルカン（アウレオバシジウム培養液）の医療、保健、福祉、食品および各種産業分野での応用
KR20070034211A (ko) * 2005-09-23 2007-03-28 주식회사 글루칸 β-글루칸을 포함하는 항암 및 면역 기능 증강용 약학조성물
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
CN107106687A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
WO2016073763A2 (en) * 2014-11-06 2016-05-12 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
WO2017120604A1 (en) * 2016-01-08 2017-07-13 Biothera, Inc. Beta-glucan immunotherapies affecting the immune microenvironment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YOSHUIYUKI KIMURA ET AL.: "Antitumor and antimetastatic activity of a novel water-soluble low molecular weight beta-1, 3-D-glucan (branch beta-1, 6) isolated from Aureobasidium pullulans 1A1 strain black yeas", 《ANTICANCER RES》, vol. 26, no. 6, 30 November 2006 (2006-11-30), pages 4131 - 4141, XP008127349 *
张亚茹 等: "黑酵母β-1, 3-1, 6-葡聚糖对小鼠肿瘤及免疫功能的影响", 《食品科学》, vol. 33, no. 19, 15 October 2012 (2012-10-15), pages 306 - 309 *
郑建仙主编: "《功能性食品 第2卷》", 30 September 1999, 中国轻工业出版社, pages: 81 - 84 *

Also Published As

Publication number Publication date
CN120678911A (zh) 2025-09-23
JP7088502B2 (ja) 2022-06-21
WO2021049587A1 (ja) 2021-03-18
EP4029509A1 (en) 2022-07-20
US12377116B2 (en) 2025-08-05
US20220265698A1 (en) 2022-08-25
EP4029509A4 (en) 2023-10-18
JPWO2021049587A1 (https=) 2021-03-18

Similar Documents

Publication Publication Date Title
Wu et al. Antitumor effect of soluble β-glucan as an immune stimulant
US6956120B2 (en) β-1.3-1.6 glucan (Aureobasidium medium)
KR100649855B1 (ko) β-글루칸 함유 조성물 및 상기 조성물을 이용한 변비개선제, 면역 부활제 및 피부용 보습제
Masuda et al. Antitumor activity of orally administered maitake α-glucan by stimulating antitumor immune response in murine tumor
Hobbs The chemistry, nutritional value, immunopharmacology, and safety of the traditional food of medicinal split-gill fugus Schizophyllum commune Fr.: Fr.(Schizophyllaceae). A literature review
Devi et al. Immune augmentation and Dalton's Lymphoma tumor inhibition by glucans/glycans isolated from the mycelia and fruit body of Pleurotus ostreatus
US12156884B2 (en) Cancer treatment using β-(1-3)-(1-4)-glucan
JP4369258B2 (ja) 免疫賦活剤
Han et al. Antimetastatic and immunomodulating effect of water extracts from various mushrooms
US20050271613A1 (en) Beta-1, 3-1, 6-D-glucan and its use
Jeong et al. Antitumor and immunomodulating activities of endo-biopolymers obtained from a submerged culture of Pleurotus eryngii
CN114340669A (zh) 用于增强抗体药物的效果的组合物
Sima et al. Glucans and cancer: Historical perspective
WO2020249132A1 (zh) 一种葡聚糖在制备药物的应用
Masuda et al. Macrophage J774. 1 cell is activated by MZ-Fraction (Klasma-MZ) polysaccharide in Grifola frondosa
KR100278928B1 (ko) 펠리누스린테우스로부터분리한다당류물질의신규한용도
CN114008083A (zh) 一种β-葡聚糖组合物及其用途
JP6842014B2 (ja) トロンボスポンジン１遺伝子発現亢進用組成物
US20030064076A1 (en) Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food
TW591105B (en) Novel immuno-stimulating polysaccharide substance from Phellinus spp. strain and use thereof
CN1314963C (zh) 含有香菇菌丝体提取物的lak活性筛选材料以及使用该提取物的lak活性筛选方法
US6919081B1 (en) Lak activity potentiator orginating in shitake mushroom hyphae extract and lak activity potentiating preparations containing the same
US20040001856A1 (en) Extract of lentinus lepideus and composition comprising the same having immune enhancing activity
CN105412155A (zh) 拟康氏木霉胞外多糖治疗和预防结肠癌的应用、及其联用化疗药物治疗结肠癌的应用
Polishchuk et al. Biological activity of glycopolymers from Basidiomycetes mushrooms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220412